9 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Seagen Inc. | 8 |
| Seagen Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18282322 | ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Seagen Inc. | HECK, BRYAN WILLIAM | 1643 | Non-Final OA | Sep 15, 2023 |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Seagen Inc. | ALLEN, MARIANNE P | 1647 | Non-Final OA | Sep 15, 2023 |
| 18027557 | METHODS OF TREATING SOLID TUMORS DRIVEN BY HER2 ALTERATIONS WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY | Seagen Inc. | NICKOL, GARY B | 1643 | Non-Final OA | Mar 21, 2023 |
| 18178418 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | Seagen Inc. | HAVLIN, ROBERT H | 1626 | Non-Final OA | Mar 03, 2023 |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | Seagen Inc. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Final Rejection | Jan 25, 2023 |
| 18016648 | METHODS AND SYSTEMS FOR PRODUCING POLYPEPTIDES | Seagen Inc. | TSAY, MARSHA M | 1656 | Non-Final OA | Jan 17, 2023 |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | Seagen Inc. | XIAO, YAN | 1642 | Non-Final OA | Nov 18, 2022 |
| 17786107 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUANTIFICATION OF EXCIPIENTS | Seagen Inc. | VARMA, AKASH K | 1773 | Non-Final OA | Jun 16, 2022 |
| 17775492 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Seagen Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | Non-Final OA | May 09, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial